Lyka Labs

Lyka Labs Quick Ratio

The Quick Ratio (Acid Test) of Lyka Labs (LYKALABS.NS) as of Oct 28, 2026 is 0.27. In the previous year, Quick Ratio (Acid Test) was 0.99 — a change of -72.81% (lower).

Quick Ratio

0.27

YoY

-72.81%

Last updated:

Quick Ratio (Acid Test) of Lyka Labs is 2026 0.27 . Quick Ratio (Acid Test) of Lyka Labs was 2025 0.99 . It decreases by -72.81% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lyka Labs Stock analysis

What does Lyka Labs do? Lyka Labs Ltd. generates revenue through the manufacture and sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company produces dry powder, liquid injections, lyophilized injections, ointments, creams, lotions, and external preparations for international and domestic markets. Its product portfolio includes emollient, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, proton pump inhibitors, anti-fungal, anti-malarial, anti-bacterial, corticosteroid hormones, and cephalosporins. The firm's subsidiaries, Lyka BDR International Limited and Lyka Exports Limited, support its global distribution and export activities. Lyka Labs Ltd. targets international markets and the domestic market for its pharmaceutical products. The company focuses on lyophilization for sterile APIs and novel drug delivery systems in topical preparations and lyophilized products. Its formulations cater to diverse therapeutic areas including dermatology, gastrointestinal health, and antimicrobial treatments. The firm's manufacturing capabilities enable it to supply products directly to healthcare providers and pharmaceutical distributors. The company's revenue streams are derived from the sale of its diverse product range to both international and domestic customers. Lyka BDR International Limited and Lyka Exports Limited facilitate the export of pharmaceutical products to global markets. Lyka Labs Ltd. emphasizes new product development, particularly in lyophilized formulations and topical preparations, to meet evolving market demands. Its focus on sterile APIs and novel drug delivery systems positions it to serve specialized healthcare segments. Lyka Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lyka Labs stock

Quick Ratio (Acid Test) of Lyka Labs is 0.27 in 2026.

Quick Ratio (Acid Test) of Lyka Labs changed from 0.99 to 0.27, representing a -72.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Lyka Labs since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Lyka Labs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Lyka Labs

All Key Metrics — Lyka Labs